**Registered number: 10529899 Charity number: 1173589** **PTEN RESEARCH FOUNDATION FINANCIAL STATEMENTS YEAR ENDED 31 MARCH 2022** **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **CONTENTS** ||Page| |---|---| |**Reference and administrative details of the Charity, its Trustees and advisers**|1| |**Trustees' report**|2 - 12| |**Independent auditors' report on the financial statements**|13 - 15| |**Statement of financial activities**|16| |**Balance sheet**|17| |**Statement of cash flows**|18| |**Notes to the financial statements**|19 - 34| **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS** **FOR THE YEAR ENDED 31 MARCH 202** |**Trustees/Directors**|Riccardo Zacconi| |---|---| ||Renata Crome (appointed 11thMay 2021)| ||Susannah Clark| ||Siriana Baldini (appointed 11thMay 2021)| ||Dr Philip Bedford (resigned 19thJanuary 2022)| ||Dr Robert Williams (appointed 21stJanuary 2022)| |**Company Registered Number**|10529899| |**Charity Registered Number**|1173589| |**Registered Office**|4thFloor St James House| ||Cheltenham GL50 3PR| |**Independent auditors**|Crowe U.K. LLP| ||4thFloor St James House| ||Cheltenham GL50 3PR| |**Investment Manager**|Brown Advisory| ||18 Hanover Square| ||London, W1S 1JY| |**Bankers**|Barclays Wealth| ||Mayfair| ||London W1K 1AF| ||JP Morgan SE| ||6 Route de Treves| ||L-2633 Senningerberg| ||Luxembourg| Page 1 **(A company limited by guarantee)** ## **PTEN RESEARCH FOUNDATION** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** The Trustees, who are also Directors for the purposes of Company Law, present their annual report together with the audited financial statements of the charity for the year 1st April 2021 to 31st March 2022. The Trustees confirm that the Annual Report and financial statements of the company comply with the current statutory requirements, the requirements of the company's governing document and the provisions of the Statement of Recommended Practice (SORP), applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). ## **Trustees** The trustees who served during the period were: Riccardo Zacconi (Director and Trustee) Susannah Clark (Director and Trustee) Dr Phillip Bedford (resigned 19[th] January 2022) Renata Crome (appointed 11[th] May 2021) Siriana Baldini (appointed 11[th] May 2021) Robert Williams (appointed 21[st] January 2022) Riccardo Zacconi has signed the report on behalf of the Board of Trustees and the Directors. ## **Members** The company currently has a single member, Blue Compass PTC Limited, which has been in place since 16[th] December 2016. ## **Structure, governance and management** ## **1. Name of the governing document and how the charity is constituted** The PTEN Research Foundation ('the Foundation' or 'PTEN Research') was established as a charity under English and Welsh law in 2017 (registered number 1173589). The Foundation is constituted under a Memorandum of Association and Articles of Association, dated 16[th] December 2016, which were revised by a special resolution of the Foundation’s member on 18[th] July 2022 (the ‘Revised Articles’). The Foundation's mission is to fund and facilitate research that will lead to new and better treatments for PTEN hamartoma tumour syndrome (‘PHTS’). ## **2. Methods used to recruit and appoint new trustees** Under the Revised Articles, PTEN Research must have not less than three trustees and unless and until the Charity determines otherwise by ordinary resolution, the number of its trustees is not subject to a maximum limit. The appointment, recruitment, and terms of office of trustees are determined by the governance needs of the Foundation to meet its mission. New trustees are recruited through relevant scientific, research or business networks. Active consideration is given to the diversity of the Board. Any person who is willing to act as a trustee and is permitted by law to do so, may be appointed by an ordinary resolution of the member. To date trustees have been appointed based on their skills and knowledge, and the contribution they can offer the Foundation. Page 2 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **3. The charity’s organisational structure and how decisions are made** The organisational structure of the Foundation is as follows: - Board of Trustees: the governing entity; the board ratifies policy and makes operational, funding and strategic decisions by majority vote. - Staff: responsible for carrying out the day-to-day activities of the charity in accordance with its charitable objectives. They are supervised by the trustees and supported in their decision making through a Delegated Scheme of Authority. - Scientific Advisory Board (SAB): responsible for providing the Foundation with non-binding scientific advice on its programmes and strategy. At PTEN Research, decisions are made by the trustees or by delegation of authority to staff who manage the daily running of the Foundation. Under the Revised Articles, decisions of the Board must be supported by a majority of the trustees either in person or in writing. The trustees and member can exercise the powers of the charity as described in the published Revised Articles. As at 31st March 2022, and as at the date of this report, the Foundation's Board of Trustees included five individuals with knowledge in the fields of drug development, finance, communications, law and business development. The trustees meet at least four times a year. The Foundation has a small team of staff who have the delegated authority to oversee the day-to-day running of the charity, ensuring that it adheres to its charitable objectives and mission. At 31st March 2022, the Scientific Advisory Board (the ‘SAB’) comprised eight experts whose specialisms included: medicine, scientific research, drug development, basic research, clinical research and genetics. The SAB meets on average once a year to discuss the scientific progress of the Foundation. The SAB is also consulted during the year to advise on grants or to give input into scientific projects. It has an advisory role and no decision-making authority. ## **4. Policies and procedures for induction and training of trustees** On appointment, new trustees sign a trustee declaration statement committing their time and expertise to the Foundation. After an initial meeting at which new trustees meet the Foundation’s staff, they are introduced to the Foundation’s grant making process, policies and procedures, and other relevant activities. New trustees are given access to the Foundation's governing documents, HR policies, financial information, annual reports and accounts, meeting materials and essential trustee guidance provided by the Charity Commission. In May and June 2022, Trustees were provided with two training modules commissioned from an external consultant, which covered trustees’ duties and responsibilities as required by law and best practice. ## **5. Arrangements for setting pay and remuneration of key management personnel** Trustees are not remunerated for their work. Trustee expenses are reimbursed in line with Foundation policy. Pay and remuneration of key management staff is set by the trustees after a review of relevant market data. Key management staff comprise the Chief Executive, the Director of Translational Medicine, the Director of Research and the Director of Finance and Business Operations. Staff pay and remuneration are reviewed annually. Page 3 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **6. The Charities (Protection and Social Investment) Act 2016** The Foundation is a larger charity as defined by S144(2) of the Charities Act 2011. As such, under The Charities (Protection and Social Investment) Act 2016, it must provide information and undertakings in respect of fundraising activities carried out during the period under review in its trustees’ report. During the year ended 31st March 2022, the Foundation did not engage a professional fundraiser or commercial participator or any other person to raise funds on its behalf; neither the Foundation nor anyone acting on its behalf was subject to an undertaking to be bound by any voluntary scheme for regulating fund-raising, or any voluntary standard of fundraising; and no complaints were received by the Foundation or any person acting on its behalf about fund raising activities. The Foundation’s website states that volunteers are not authorised to raise funds on its behalf, and that volunteers who choose to raise funds in aid of the Foundation are solely responsible for all aspects of those activities, for which the Foundation has no liability. The Foundation’s website encourages ‘in aid of’ fundraisers to act within the law. ## **Objectives and Activities** ## **1. Purposes of the charity and strategy** Under its governing documents, the Foundation's purposes are specifically restricted to: _"the protection and promotion of the health of individuals diagnosed with PTEN hamartoma tumour syndrome (PHTS) or other related conditions (by mechanism, clinical presentation or other factors) in particularly by research into the nature, causes, diagnosis, prevention, treatment and cure of PHTS or other related conditions, including the development of findings of research into practical applications for the prevention, treatment and cure of PHTS or other related conditions, and in furtherance of that primary object, to increase awareness of PHTS or other related conditions and provide information and support as appropriate to affected individuals and families; and all purposes that are of public benefit and are exclusively charitable under the law of England and Wales."_ PHTS is a rare genetic disease caused by alteration (mutation) in the PTEN gene. These alterations may be inherited from the mother or father, or they may occur spontaneously during embryonic development. They result in a variety of symptoms and signs, including macrocephaly (enlarged head circumference), learning difficulties, autism spectrum disorder, vascular (blood vessel) anomalies, gastrointestinal polyps (growths in the gut), and hamartomas (benign lesions of the skin and other tissues). In addition, people with PHTS have an increased lifetime risk of developing cancer, particularly cancers of the breast, thyroid, and endometrium (lining of the womb). Due to its variable presentation, the true prevalence of PHTS in the general population is not known but is estimated to be about 1 in 200,000, although this is likely to be an underestimate. Indeed, approximately 2% of all ASD cases and up to 20% of patients with ASD and macrocephaly are reported to have the germline pathogenic PTEN mutations. There are currently no health authority-approved treatments specific to PHTS, and clinical management of patients is largely focused on cancer surveillance and supportive care, which are associated with a high burden on healthcare systems. There is therefore a high unmet need for therapies to treat and, ultimately in the future, to potentially prevent the various symptoms associated with PHTS, as well as to improve the understanding of the syndrome to enable more accurate prognoses and improved management for diagnosed individuals. Developing therapies which mitigate the high burden on health systems is therefore for the wider public benefit. The Foundation’s strategy centres on the generation of preclinical and clinical evidence that will enable the Foundation, and others (both academic collaborators and industry), to develop treatment options for PHTS. We will continue to cultivate a portfolio of clinical development opportunities by supporting ongoing research efforts and establishing new partnerships. At a cellular level, the genetic alterations to the PTEN gene that result in PHTS cause dysregulation of the PI3K/AKT/mTOR pathway. This pathway has been the subject of extensive scientific study because it is often abnormal in acquired (sporadic) cancers that occur in the general population. As result, it may be possible to repurpose inhibitors of the PI3K/AKT/mTOR pathway that were originally developed to treat common cancers in the general population and other conditions, to treat individuals with PHTS. Page 4 **PTEN RESEARCH FOUNDATION** **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** The Foundation carries out its objects by implementing activities that support delivery of its strategy as depicted in Figure 1. **Figure 1: The Foundation’s strategic goals & critical enabling activities** **----- Start of picture text -----**
Therapies for PHTS
Goal 1: Therapy options for
non-malignant symptoms
Goal 2: Management and
prevention of cancer
Understanding Sustainable
Partnerships
of PHTS Foundation
Goals
Enablers
**----- End of picture text -----**
The central focus of our work is the development of therapy options for the non-malignant symptoms of PHTS that are clinically tractable and have a clear unmet need (Goal 1). In addition, the Foundation is increasingly focused on activities associated with PHTS and malignant disease (Goal 2), including diagnosis and cancer surveillance, and management of malignant disease. Whilst continuing to be a longer-term aspiration of the Foundation, cancer prevention strategies are highly challenging at present. Activities that are integral to ensuring the success of therapy development efforts, but not strategic goals per se, are detailed as ‘Enablers’. These encompass research efforts to improve understanding of both the biology of PTEN and PHTS, development of partnerships with key stakeholder groups, and development of a financially sustainable Foundation. The work undertaken to fulfil the Foundation’s objectives in the field of PHTS may have beneficial effects that extend well beyond PHTS. In particular, basic scientific and clinical research aimed at understanding the pathobiology of cancer in PHTS may improve the understanding of cancers more generally. Similarly, work on vascular anomalies, soft tissue overgrowth and hamartomas in PHTS, has the potential to benefit patients with other genetic disorders which predispose to these conditions, as well as patients with sporadic non-syndromic conditions. Also, in the field of neuroscience, there are number of other neurodevelopmental conditions characterised by genetic alterations in cellular pathways that overlap with or are linked to, the PI3K/AKT/mTOR pathway. These include tuberous sclerosis complex (caused by alterations in the TSC1 and TSC2 genes) and Phelan-McDermid syndrome (caused by SHANK3 gene alterations). Clinical and scientific knowledge gained in PHTS has the potential to support advancement in these related conditions and beyond, for example, in non-syndromic autism spectrum disorder. Finally, PHTS is a rare disease and conducting trials in rare diseases brings particular challenges. Approaches taken by the Foundation may help others who face similar issues. For example, the development of new and more efficient trial designs and disease-specific trial endpoints, partnering with pharmaceutical and biotech companies and contract research organisations (as well as academic collaborators), and early engagement with regulatory agencies, may provide paradigms for other charitable organisations working in rare diseases. The Foundation’s strategy, future plans, and budgets are annually reviewed and agreed by the trustees. Page 5 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **2. Activities undertaken in the year** The total income received for the period ending 31st March 2022 was £924,635. This income was a result of the following activities: - Restricted donations received: £3,361. As a result of volunteer fundraising efforts, restricted donations were given to the Foundation for the purposes of funding medical research projects. - Unrestricted donations received: £nil - Investment income received: £921,274. The total expenditure for the year ending 31st March 2022 was £3,702,779. This expenditure supported the Foundation's core activities to set in place the strategy, process and governance bodies to fund clinical trials and medical research projects. The Foundation's core activities were focused on commissioning work and granting activities to set up awards for scientific research in line with the Foundation's strategy. The Foundation also consulted with many subject matter experts including the US Food and Drug Administration on a range of topics and progressed business development opportunities. The Foundation maintains a dialogue with PHTS patient advocacy groups to support an understanding of the work that the Foundation is undertaking. Work continued with industry and an academic institution, on the process of discovery into novel drug development for PHTS. ## **3. Criteria used to assess the success of the reporting period** The Trustees meet at least once a quarter. A standing item of the board meetings is to assess the progress of the Foundation against its agreed annual goals, project progress as detailed in the Foundation’s dashboard and strategic objectives. ## **4. Review of significant activities undertaken to further charitable objectives for the public benefit** ## **Statement of Confirmation** The Trustees confirm that they have given due consideration to the Charity Commission’s published guidance on the public benefit requirement under Charities Act 2011. They believe the development of therapy options for PHTS patients (the Foundation’s primary object) will alleviate the high burden on healthcare systems associated with the largely unmet needs of PHTS patients today, as is further explained in the overview below. ## **Overview: activities undertaken to further charitable objectives for the public benefit** The Foundation’s principal charitable objective is to protect and promote the health of individuals diagnosed with PTEN hamartoma tumour syndrome (PHTS) or other related conditions. Despite the ongoing impact of the COVID-19 pandemic, the Foundation continued to make significant progress to further its principal charitable objective for the public benefit during the period 1st April 2021 to 31st March 2022. There were 19 active projects at the year-end, of which 16 were with academic collaborators and the rest with commercial partners. Several projects were in active development. Significant progress was made on several key scientific projects: - A new grant focusing on PHTS vascular anomalies (VA) was awarded to Children’s Hospital of Philadelphia. The goal is through expert review of clinical, pathology and radiology data from PHTS cohorts in the US and Europe to validate a PHTS VA specific classification approach with the goal of supporting future clinical trials. Page 6 ## **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** - A grant led by Radboud University in the Netherlands focusing on retrospective analysis of data from a European cohort of PHTS patients to refine the risk of cancer was successfully completed and the final manuscript submitted for publication. - Reflecting the importance of developing approaches to facilitate future clinical trials in PHTS subjects, the Foundation collaborated with grant holders at the University of Melbourne and John Carroll University on previously approved grants to seek guidance from the US Food and Drug Administration on the proposed development and validation plans of the respective projects. It is hoped that these grants will result in tools that may become endpoints for future clinical trials. - A proposal for an International Classification of Diseases (ICD-10-CM) code for PHTS was presented to the US Center for Disease Control and Prevention (CDC) in September 2021 and a corresponding application for an ICD-11 code was made to World Health Organisation (WHO) in May 2021. - The Foundation's preclinical work is focused on the development of relevant preclinical models in which to perform drug repurposing studies to provide supportive data and rationale for future PHTS patient clinical trials. Initially, the studies are focused on a range of existing molecules that have been developed to specifically inhibit the key signaling nodes of the Pl3K/AKT/mTOR pathway. Inhibitory activity will be assessed both _in vitro_ and _in vivo_ in models that are dependent on loss of PTEN function. During the year significant progress was made towards model development targeting malignancy (endometrial hyperplasia), vascular anomalies and neurology with multiple academic collaborators. Further, collaborations with the Contract Research Organisations (CROs) Evotec and Charles River Laboratories have broadened the range of available PHTS-specific models and provide capacity to evaluate large numbers of drug repurposing candidates in contrast to the more bespoke studies with academic collaborators. - A collaboration with the vascular biology group at Josep Carreras Leukaemia Research Institute in Barcelona which has established a model of PHTS vascular malformations is ongoing with preliminary data from two potential clinical candidates now available. - The Foundation launched a formal targeted call with the goal of providing grants to elucidate improved understanding of the role of non-canonical functions of PTEN in PHTS. Sixteen full applications were received and underwent external peer review with a short list being prepared for further review by the Foundation’s SAB and Trustees. - A Foundation-led virtual scientific meeting was held. Key funded researchers and collaborators in the field were invited to present summaries of their current research to further enhance sharing of knowledge and promote synergy amongst the PHTS research community. Positive feedback was received. ## **Governance:** In the year ending 31[st ] March 2022, the Foundation continued to strengthen its governance. A governance review was commissioned from an external consultant, which has led to the development of a new dedicated trustee and governance policy, revised conflict of interest policies and revisions to our articles of association. Processes for regular reporting and risk escalation to ensure transparent and informed decision-making continue to be used to guide the Foundation's grants and work. ## **Strategy:** The Foundation's strategy is continually refined and updated. A longer-term plan of activities to deliver the strategy is proactively maintained and costed for the period to 2029. ## **Staff:** In November 2021, recognising the growth and maturation of the Foundation, the trustees appointed a Director of Finance and Operations and, in January 2022, two Scientific Project Managers. The drivers for these appointments include the increased volume of activities and associated budget; and the need to ensure appropriate scientific prioritisation and enhanced internal decision-making, including portfolio management. ## **Policies, Guidance Documents and Process:** The Foundation continues to maintain and develop policies and processes for HR, operations, financial awards and fundraising, as required. Page 7 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **Clinical Development Working Groups (CDWGs):** These are multidisciplinary groups of international PHTS thought leaders supporting the Foundation with outputs envisaged to play a key role in shaping and optimising the design of future prospective PHTS clinical, natural history and translational medicine studies with a goal of improving patient care more broadly. The continued development of the CDWGs over the last year has provided significant value to the Foundation. ## **Patient engagement:** The Foundation has maintained regular interactions with patient advocacy groups. (Historically, staff have attended PHTS patient days, however, such activities were naturally placed on hold because of the COVID-19 pandemic.) The Foundation cannot offer specific advice to individual patients. ## **Analysis of publicly available scientific and medical literature:** Desk research continues to be held on publications relating to the natural history and the mechanism of disease of PHTS. Trustees and the staff team regularly review these developments to ensure the Foundation's activities remain relevant and robust. ## **Policy on grant and non-grant funding:** The Foundation provides grants in line with its strategic goals and mission. The Foundation funds research projects that can translate into better treatments for PHTS patients. This includes clinical research studies, interventional clinical trials, preclinical/translational research projects and, where appropriate, basic research projects. Funding is primarily provided through two mechanisms: - Targeted calls - Innovation Awards Discussions arising from the Clinical Development Working Groups have also led to several grant applications. Grants are awarded to Principal Investigators who have qualified with an MD or PhD and who have an established research programme in a recognised academic or clinical research institution. Eligibility is not restricted to any specific geography. Funding is intended to support all essential costs relating to a project, including staff, consumables, equipment, travel and publication costs. The Foundation’s policy is to pay only those costs that are directly attributable to the activities of the grant. Applications undergo a scientific, strategic, and programmatic assessment by the Foundation's internal research team. Successful applications at this stage are then generally submitted for external peer review by at least two independent subject matter experts. The peer-reviewed applications are then subject to review by the Scientific Advisory Board (SAB) prior to a final approval by trustees. In addition to grants, the Foundation commissions work with industry partners including contract research organisations (CROs) in the pursuit of its mission. This contracted work undergoes a scientific, strategic and programmatic assessment by the Foundation's internal research team before work commences. ## **Fundraising:** The Foundation received £3,361 in donations (all restricted). ## **1. Use of volunteers** At present the Foundation does not utilise volunteer staff. As previously noted, trustees are engaged on a voluntary basis. Page 8 **PTEN RESEARCH FOUNDATION** **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **(A company limited by guarantee)** ## **2. Fundraising activities** The Foundation is primarily funded through one-off donations and income from its investments. In addition, the Foundation has recently prepared a fund-raising strategy paper and is in discussion with several professional charity fund raising groups, one of which may be engaged later in the year. When negotiating legal agreements, including grant terms and conditions, the Foundation actively seeks to equitably share with its academic and commercial partners any potential arising intellectual property ownership, commercialisation rights and/or royalties relative to the proportion of the total costs funded by the Foundation. Further, by highlighting the unmet medical need of PHTS to pharmaceutical and biotech organisations coupled with potential regulatory incentives associated with both paediatric and rare disease drug development applicable to PHTS, we hope that such organisations may not only provide direct financial support to the charity to access preclinical models developed by the Foundation but also may independently support PHTS drug development. ## **Risk management:** We recognise the inherent risks associated with the development of therapy options for a rare disease such as PHTS given the complexity of the syndrome and low number of patients worldwide. In common with other organizations supporting drug development and life sciences, not all projects supported by the Foundation can be expected to have a positive outcome. However, negative outcomes can often inform our future strategy and provide valuable scientific data and learnings. Potential risks include, but are not limited to, the potential failure of preclinical studies and/or clinical trials to meet safety or efficacy endpoint criteria, the potential unwillingness of industrial partners to support PHTS development, and the challenges of meeting the requirements of global Health Authorities to ensure drug approvals in the rare disease setting. In some cases, we will actively choose to undertake multiple activities in parallel to enhance the probability that we will ultimately fulfil our mission, as well as gate certain future activities on the read-out of predecessors. To ensure good stewardship of charitable funds the Foundation actively seeks the guidance of key opinion leaders in the PHTS field worldwide both via the Scientific Advisory Board and the Clinical Development Working Groups. Further, grants continue to be independently peer reviewed, follow robust contracting procedures and are subject to active monitoring and evaluation by Foundation staff. The COVID-19 pandemic continues to have a major impact on global health systems, including the management and delivery of preclinical and clinical research. (Whilst restrictions on day-to-day life are currently being relaxed, healthcare systems face pressures in relation to catching up with clinical case backlogs and staffing issues that have resulted from the previous disruption.) We continue to monitor the situation closely in the context of ongoing and future planned activities with our key partners. We have supported the development of COVID-19 specific mitigation plans, including reviewing impacts on timelines and resources. It may be that the pandemic forces the acceleration of disruptive innovation with respect to drug development (e.g., designing clinical trials where more study assessments are undertaken at or close to a participating family’s home vs. requiring multiple face-to-face visits to a distant trial centre). Another consideration is the current clinical development focus on rapalogs, compounds known to have immunosuppressive pharmacology in context of a pandemic. (This said, a recent randomized controlled trial of everolimus for neurocognitive symptoms of PHTS (NCT02991807) was completed during the pandemic, and all patients/families in the doubleblind phase of the trial elected to continue their participation.) We are following the experience of other rare disease patient groups who routinely receive rapalogs (e.g., tuberous sclerosis complex and lymphangioleiomyomatosis subjects) and the frequency and severity of COVID-19 infections in these groups relative to the background population in the context of rapalog use. Preliminary data from two reports that were published prior to the availability of vaccinations appear to be reassuring. Page 9 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** To enable active portfolio and risk management, the Foundation uses a project dashboard with visualisations of our portfolio of projects by phase, associated project risks, and financial analyses. It is acknowledged that, in the future, a more active approach to portfolio management will be needed, based not only on emerging data and which projects are most likely to lead to a future treatment for PHTS patients but which also considers the need for the Foundation to operate within its available funds. We utilise standard industry attrition rates of projects by phase to inform decision making and portfolio management and undertake a 6-monthly review of forecast of expected annual expenditure for the following 8-10-year period, in both fully loaded and attritionadjusted models. Potential risks also arise in relation to our finances. Though we have a generous endowment, our resources are finite. The Foundation has a bond portfolio whose constituents are held to maturity and are expected to cover expenditure until March 2027; and a growth investment portfolio which might reasonably be expected to cover 2 to 4 years expenditure after that. If inflationary conditions persist, however, the bond portfolio may fall short of the outgoings it is designed to fund. Moreover, the value of the growth portfolio depends on financial markets which have suffered from the war in Ukraine, inflation, rising interest rates and fears of recession. The following other risks have been identified in our operational risk register and remedial action taken. - Following a Charity Commission alert issued on behalf of the National Cyber Security Centre, we revised our IT policy and instituted staff training on best practice in the first quarter of 2022. - Conscious of the need for good internal controls, we strive to remedy weaknesses identified by our auditors, and now maintain our own investment records following an audit recommendation in 2021. - Given that staff work from home, and the risk that this may detract from staff’s ability to work as a cohesive team, we have supplemented virtual staff interaction with monthly physical meetings, and organisational training provided by an independent consultant. - In recognition of the fact that our constitution had not been reviewed since incorporation in 2017, we engaged Stone King, solicitors, to review our articles of association, which were revised in July 2022. - Finally, to ensure good governance, we commissioned a governance review from an independent consultant, following which our trustee policy was updated and the same consultant has provided training to our trustees. ## **Financial Review:** ## **1. Review of the charity’s financial position as at the end of the reporting period** At the end of the reporting period the Foundation holds no restricted funds. The Charity holds general funds of £30,150,258 to be used for direct and support costs over the period to 31st March 2029. ## **2. Investment management** Following a formal review and retendering of the investment management function with the goal of ensuring appropriate liquidity to meet the Foundation’s short-term liabilities whilst also maximising the opportunity for investment growth, Brown Advisory were engaged as the Foundation’s new and exclusive investment manager in April 2021. Brown have created a bond portfolio to cover the Foundation’s expenditure until end of March 2027; and a growth investment portfolio to cover 2 to 4 years expenditure after that. Of the securities held in these portfolios, at least 85% must be realizable into cash within 5 business days; and up to a maximum 15% within 45 business days. ## **3. Reserves Policy and Going Concern** The Foundation does not implement a reserves policy. Page 10 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** All restricted and unrestricted donations received to date have been accounted for in the Foundation's accountancy software and are clearly split with respect to purpose and use. With due regard to the Foundation’s finances and projected expenditure, the trustees remain satisfied that it has sufficient resources to continue as a going concern for at least 12 months after the approval of the financial statements to which this report relates. ## **4. Plans for Future Periods** In the coming year, the Foundation's existing granted and industry-based collaborations will continue to progress. The Foundation will continue to forge links with members of the professional and patient communities, with the aim of facilitating future collaborative working. To this end, the Foundation intends to hold further scientific meetings with its funded researchers and collaborators to enhance sharing of knowledge and promote synergy. Foundation staff will continue to participate in other events, meetings and patient days, where appropriate. In the immediate term, we plan to sign grant award letters with two applicants who responded to our targeted call in 2021 for grants specifically to elucidate and support improved understanding of role of non-canonical functions of PTEN in PHTS. Page 11 ## **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** **TRUSTEES' REPORT FOR THE YEAR ENDED 31 MARCH 2022** ## **Trustees' Responsibilities Statement** The Trustees (who include all the directors of PTEN Research Foundation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to: - select suitable accounting policies and then apply them consistently; - observe the methods and principles in the Charities SORP and FRS 102; - make judgments and accounting estimates that are reasonable and prudent; - prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation. The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. ## **Disclosure of information to Auditors** Each of the persons who are Trustees at the time when this Trustees' Report is approved has confirmed that: - so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and - that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information. In preparing this report, the Trustees have taken advantage of the small companies' exemption provided by section 415A of the Companies Act 2006. This report was approved by the Trustees, on 16[th] November 2022 and signed on their behalf by: ## **Riccardo Zacconi** Trustee, PTEN Research Foundation Page 12 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **Opinion** We have audited the financial statements of PTEN Research Foundation (‘the charitable company’) for the year ended 31 March 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice). In our opinion the financial statements: - give a true and fair view of the state of the charitable company’s affairs as at 31 March 2022 and of its income and expenditure, for the year then ended; - have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and - have been prepared in accordance with the requirements of the Companies Act 2006. ## **Basis for opinion** We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. ## **Conclusions relating to going concern** In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report. ## **Other information** The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements, or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. Page 13 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **Opinions on other matters prescribed by the Companies Act 2006** In our opinion based on the work undertaken in the course of our audit - the information given in the trustees’ report, which includes the directors’ report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and - the directors’ report included within the trustees’ report have been prepared in accordance with applicable legal requirements. ## **Matters on which we are required to report by exception** In light of the knowledge and understanding of the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the trustees’ report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion: - adequate and proper accounting records have not been kept; or - the financial statements are not in agreement with the accounting records and returns; or - certain disclosures of trustees' remuneration specified by law are not made; or - we have not received all the information and explanations we require for our audit. ## **Responsibilities of trustees** As explained more fully in the trustees’ responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so. ## **Auditor’s responsibilities for the audit of the financial statements** Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below. A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report. Page 14 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF PTEN RESEARCH FOUNDATION** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **Extent to which the audit was considered capable of detecting irregularities, including fraud** Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team members. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion. We obtained an understanding of the legal and regulatory frameworks within which the charitable company operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006, together with the Charities SORP (FRS102) 2019. We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items. In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company’s ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company for fraud. Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any. We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Audit Committee about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission and reading minutes of meetings of those charged with governance. Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing noncompliance and cannot be expected to detect non-compliance with all laws and regulations. ## **Use of our report** This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed. **Tara Westcott** Senior Statutory Auditor For and on behalf of: Crowe U.K. LLP, Statutory Auditor 4[th] Floor St James House, St James’ Square, Cheltenham. GL50 3PR Date: 14 December 2022 Page 15 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **STATEMENT OF FINANCIAL ACTIVITIES INCORPORATING INCOME AND EXPENDITURE ACCOUNT** ## **FOR THE YEAR ENDED 31 MARCH 2022** |**Note**|**Unrestricted**
**Funds**
**2022**
**£**
**Restricted**
**funds**
**2022**
**£**
**Total**
**funds**
**2022**
**£**
**Total**
**funds**
**2021**
**£**| |---|---| |**Income from:**|| |Donations
2|3,361
3,361
418| |Investments
3|921,274
921,274
722,491| |**Total income**|921,274
3,361
924,635
722,909| ||| |**Expenditure on:**|| |Raising funds|98,903
98,903
65,407| |Charitable activities:
4,5|0| |Direct costs|3,458,283
3,361
3,461,644
2,241,563| |Support costs|142,232
142,232
223,176| |**Total expenditure**|3,699,418
3,361
3,702,779
2,530,146| ||| |**Net expenditure before net**
**(losses) on investments**|(2,778,144)
(2,778,144)
(1,807,237)| |Net (losses)/gains on investments|(1,905,871)
(1,905,871)
312,832| |Foreign exchange gains/(losses)
on investments|621,965
621,965
(1,718,904)| |**Net movement in funds**|(4,062,050)
(4,062,050)
(3,213,309)| ||| |**Reconciliation of funds:**|| |Total funds brought forward|34,212,308
34,212,308
37,425,617| |Netmovementin funds|(4,062,050)
(4,062,050)
(3,213,309)| |**Total funds carried forward**|30,150,258
30,150,258
34,212,308| The notes on pages 19 to 34 form part of these financial statements. Page 16 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** **REGISTERED NUMBER: 10529899** ## **BALANCE SHEET** ## **AS AT 31 MARCH 2022** |**Note**|**2022**
**£**|**2021**
**£**| |---|---|---| |**Fixed assets**||| |Tangible assets
9|4,092|1,623| |Investments
10|21,817,348|17,145,083| ||21,821,440|17,146,706| |**Current assets**||| |Debtors
11
4,592|4,445|| |Investments
12
6,223,219|7,101,446|| |Cash at bank and in hand
2,397,117|10,562,58
4|| |8,624,928|17,668,47
5|| |Creditors: amounts falling due within one
year
13
(296,110)|(602,873)|| |**Net current assets**|8,328,818|17,065,602| |**Net assets**|30,150,258|34,212,308| |||| |**Charity funds**||| |Restricted funds
15|-|-| |Unrestricted funds
15|30,150,258|34,212,308| |**Total funds**|30,150,258|34,212,308| The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by ## **Riccardo Zacconi** Trustee Date: 16[th] November 2022 The notes on pages 19 to 34 form part of these financial statements. Page 17 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **STATEMENT OF CASH FLOWS** |**Cash flows from operating activities**
**Note**
Net cash provided by operating activities
17
**Cash flows from investing activities**|**2022**
**£**
(4,003,589)|**2021**
**£**
(2,240,505)
(1,199)
12,262,035
(14,390,975)
722,491
12,604,623
11,196,975
8,956,470
1,799,649
(193,535)
10,562,584| |---|---|---| |Purchase of tangible fixed assets
Proceeds from sale of investments
Purchase of investments
Investment income
Transfer to investments from cash
**Net cash provided by/(used in) investing activities**
**Change in cash and cash equivalents in the year**
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents due to exchange rate movements
**Cash and cash equivalents at the end of the year**|(5,208)
10,610,372
(15,535,585)
921,274
(167,577)
(4,176,724)
(8,180,313)
10,562,584
14,847
2,397,117|| The notes on pages 19 to 34 form part of these financial statements Page 18 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **1. Accounting policies** ## **General information** PTEN Research Foundation is a charitable company limited by guarantee incorporated in England on 16 December 2016 and registered with the Charity Commission on 27 June 2017. Its registered office address is 4[th] Floor, St James House, St James Square, Cheltenham GL50 3PR. ## **1.1 Basis of preparation of financial statements** The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. PTEN Research Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. The accounts are prepared on the basis that the Charity is a going concern. The accounts have been prepared in GBP sterling as this is the operating currency of the charity. ## **1.2 Company status** The sole member of the charity is Blue Compass PTC. In the event of the company being wound up, the liability in respect to the guarantee is limited to £1 per member of the charity. ## **1.3 Income** All income is recognised once the charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably. Donations are recognised in the period in which they are pledged. Gifts of investments are measured at fair value and are recognised on the balance sheet with a corresponding amount being recognised in income. ## **1.4 Interest receivable** Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank. ## **1.5 Expenditure** Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Page 19 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **1. Accounting policies (continued)** Charitable activities are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities. Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include governance costs. All expenditure is inclusive of irrecoverable VAT. Accounting policies are supplemented by estimation techniques where judgement is required in measuring the value of income and expenditure. Termination payments are recognised when the commitment is made to terminate employment. ## **1.6 Tangible fixed assets and depreciation** Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases: Fixtures and fittings - 33% straight line Computer equipment - 33% straight line ## **1.7 Investments** Current and fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading ‘Gains/(losses) on investments’ in the Statement of Financial Activities incorporating Income and Expenditure Account. Fixed asset investments are those investments held for the generation of investment income, investment potential or both and have a maturity of at least one year from the balance sheet date. Current asset investments are those investments held for investment purposes rather than to meet short term cash commitments as they fall due. Current asset investments are expected to be realised within 12 months of the reporting date and include cash on deposit and cash equivalents with a maturity of less than one year. ## **1.8 Debtors** Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. ## **1.9 Cash at bank and in hand** Cash at bank and in hand includes cash and short term highly liquid investments held to meet short term cash commitments as they fall due rather than for investment potential. Cash and short term highly liquid investments have a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. Page 20 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **1. Accounting policies (continued)** ## **1.10 Liabilities and provisions** Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Trade and other creditors are recognised at the settlement amount after any trade discounts received. Accruals are value based on the estimated amount to be paid. ## **1.11 Financial instruments** The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. ## **1.12 Foreign currencies** Monetary assets and liabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange gains and losses are recognised in the Statement of Financial Activities incorporating Income and Expenditure Account. ## **1.13 Pensions** The Charity operates a defined contribution pension scheme, and the pension charge represents the amounts payable by the Charity to the fund in respect of the year. ## **1.14 Fund accounting** General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements. Page 21 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## , ## **2. Income from donations and legacies** |**3.**||**Unrestricted**
**funds 2022**
**Restricted**
**funds 2022**|**Unrestricted**
**funds 2022**
**Restricted**
**funds 2022**||**Total**
**funds**
**2022**
**£**
3,361
**Total**
**funds**
**2021**
**£**
418| |---|---|---|---|---|---| |||**funds**|||| ||||||| ||||||| ||||**£**||| ||||||| ||||||| ||||||| ||||3,361||| ||Donations||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||||| ||||**Unrestricted**
**funds 2021**||| ||||||| ||||||| ||||**£**||| ||||||| ||||418||| ||Donations||||| ||||||| ||||||| ||**Investment income**||||| ||||**Unrestricted**
**funds 2022**||**Total funds**
**2022**| ||||||| ||||||| ||||||| ||||||| ||||**£**||**£**| ||||||| ||||||| ||||||| ||||||| ||||||| ||||921,274||921,274| ||Investment income||||| ||||||| ||||||| ||||||| ||||||| ||||**Unrestricted**
**funds 2021**||**Total funds**
**2021**| ||||||| ||||||| ||||||| ||||||| ||||**£**||**£**| ||||||| ||||||| ||||722,491||722,491| ||Investment income||||| ||||||| Page 22 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **4. Analysis of expenditure on charitable activities - summary by fund type** |**5.**|||**Unrestricted**
**funds 2022**
**£**||**Restricted**
**funds 2022**
**£**|**Total funds**
**2022**| |---|---|---|---|---|---|---| |||||||**£**| ||Charitable activities relating to clinical
trials and medical research||3,600,515||3,361|3,603,876| |||||||| |||||||| ||||**Unrestricted**
**funds 2021**
**£**||**Restricted**
**funds 2021**
**£**|**Total funds**
**2021**| |||||||**£**| ||Charitable activities relating to clinical
trials and medical research||2,460,960||3,779|2,464,739| ||**Analysis of expenditure by activities**||||**Support**
**costs 2022**
**£**|| ||||**Activities undertaken**
**directly 2022**|||**Total funds**
**2022**| ||||**£**|||**£**| ||Charitable activities relating to
clinical trials and medical research||3,461,644||142,232|3,603,876| |||||||| |||||||| ||||**Activities undertaken**
**directly 2021**||**Support**
**costs 2021**
**£**|**Total funds**
**2021**| ||||**£**|||**£**| ||Charitable activities relating to
clinical trials and medical research||2,241,563||223,176|2,464,739| These are costs incurred by the Foundation for its charitable purposes and comprise direct costs, which are attributable to a single charitable activity, and support costs, which are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources. Page 23 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **5. Analysis of expenditure by activities (continued)** ## **Analysis of direct costs** ||**Activities 2022**
**£**|**Total funds 2022**
**£**| |---|---|---| |||| |Staff Costs|572,557|572,557| |Clinical and preclinical research grant and contract
costs|2,889,087|2,889,087| ||3,461,644|3,461,644| Staff costs comprise wages totaling £473,469 (2021 - £418,274), employers national insurance totaling £49,614 (2021 - £45,513) and pension costs totaling £47,879 (2021 - £24,199). This also includes staff expenses of £1,945. ||**Activities 2021**
**£**|**Total funds 2021**| |---|---|---| |||**£**| |Staff Costs|487,986|487,986| |Research contracts,grants, and other direct costs|1,753,577|1,753,577| ||2,241,563|2,241,563| These direct costs are attributable to a single charitable activity. ## **Analysis of support costs** |**Analysis of support costs**||| |---|---|---| ||**Activities 2022**
**£**|**Total funds 2022**
**£**| |||| |Staff Costs|125,683|125,683| |Depreciation|1,240|1,240| |Foreign exchange gain|(160,348)|(160,348)| |General costs|106,248|106,248| |Legal & professional fees|49,513|49,513| |Bank charges|5,571|5,571| |Premises costs|-|-| |Travel costs|2,325|2,325| |Audit fees (governance)|12,000|12,000| |Loss on disposal of fixed assets|-|-| ||142,232|142,232| Page 24 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** Staff costs are made up of wages totaling £104,283 (2021 - 91,816), employers national insurance totaling £10,891 (2021 - £9,991) and pension costs totaling £10,509 (2021 - £5,312). ||**Activities 2021**
**£**|**Total funds 2021**| |---|---|---| |||**£**| |Staff Costs|107,119|107,119| |Depreciation|889|889| |Foreign exchange gain|(30,521)|(30,521)| |General costs|8,884|8,884| |Legal & professional fees|50,465|50,465| |Bank charges|22,959|22,959| |Premises costs|51,867|51,867| |Travel costs|1,322|1,322| |Audit fees (governance)|8,400|8,400| |Loss on disposal of fixed assets|1,792|1,792| ||223,176|223,176| These support costs are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources. Page 25 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** |**6.**|**Grants to Institutions**||| |---|---|---|---| |||**2022**
**£**|**2021**| ||||**£**| ||AstraZeneca|32,705|-| ||Boston Children's Hospital|74,051|193,806| ||Cambridge University|37,889|21,555| ||Charles River Laboratories|381,890|-| ||Children's Hospital of Philadelphia|25,712|-| ||Developmental Synaptopathies
Consortium|25,309|-| ||IDIBELL|43,610|-| ||Institut Josep Carreras|34,093|-| ||Radboud University Medical Center|105,624|118,573| ||Renown Health Foundation|81,638|-| ||Ohio State University|15,588|-| ||Beth Israel Deaconess Medical
Centre|-|51,113| ||University College London|365,349|234,670| ||Bellvitge Biomedical Research
Institute|-|73,718| ||TC Istanbul Bilim University|-|(2,311)| ||Biocruces Bizkaia Health Research
Institute|1,798|26,510| ||Cleveland Clinic|74,255|420,813| ||Evotec International|1,380,947|458,624| ||Imagen Therapeutics|26,234|18,140| ||John Carroll University|65,580|23,308| ||Universityof Melbourne|29,485|10,352| |||2,769,052|1,648,871| During the year grants were made to institutions in respect of research projects and clinical trials. These Grants to institutions form part of the Foundation’s direct costs, which are costs attributable to a single charitable activity. Page 26 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **7. Auditors' remuneration** ||**2022**
**£**|**2021**| |---|---|---| |||**£**| |||| |Fees payable to the Charity's auditor for the audit of the Charity's annual
accounts|10,000|7,000| |Fees payable to the Charity's previous auditor for accounting services|19,644|3,550| Auditor’s remuneration forms part of the Foundation’s support costs, which are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources. ## **8. Staff costs** |Wages and salaries
Social security costs
Other pension costs|**2022**
**£**
577,402
60,505
58,388|**2021**

**£**
510,090
55,504
29,511| |---|---|---| ||696,295|595,105| Staff costs include direct costs, which are attributable to a single charitable activity, and support costs, which are not directly attributable to a single charitable activity and are apportioned between charitable activities on a basis consistent with the use of resources. Page 27 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** The average number of persons employed by the Charity during the year was as follows: ||**2022**|**2021**| |---|---|---| ||**No.**|**No.**| |Research and support staff|6|7| The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was: |||**2022**|**2021**| |---|---|---|---| |||**No.**|**No.**| |In the band|£60,001 - £70,000|1|1| |In the band|£70,001 - £80,000|-|1| |In the band|£90,001 - £100,000|-|1| |In the band|£110,000 - £119,999|2|-| |In the band|£150,001 - £160,000|-|1| |In the band|160,001 - £169,999|1|-| ## **Transactions with Trustees** There were no transactions with trustees during the year. During the previous year donations totaling £80 were made to a school on behalf of Siriana Baldini, a trustee of the charity. ## **Transactions with Key Management Personnel** At 31 March 2022, £391 (2021 - £8) was due to key management personnel. During the year, the Charity's key management personnel received total remuneration of £568,822 (2021£499,170). Key management personnel comprised the Chief Executive and Director of Clinical Development, the Director of Translational Medicine, the Director of Research and the Director of Finance and Business Operations. The Charity entered into a settlement agreement during the year, with payments totaling £118,723. Page 28 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** **FOR THE YEAR ENDED 31 MARCH 2022** ## **9. Tangible fixed assets** |**10.**||**Computer**|**Total**| |---|---|---|---| |||**equipment**|| ||**Cost or valuation**|**£**|**£**| ||At 1 April 2021|4,305|4,305| ||Additions|5,208|5,208| ||Disposals|(1,499)|(1,499)| ||As at 31 March 2022|8,014|8,014| ||||| ||**Depreciation**||| ||At 1 April 2021|2,682|2,682| ||Charge for the year|1,240|1,240| ||On Disposals|-|-| ||As at 31 March 2022|3,922|3,922| ||||| ||**Net book value**||| ||At 31 March 2022|4,092|4,092| ||At 31 March 2021|1,623|1,623| ||**Fixed asset investments**
Valuation
At 1 April 2021
Additions
Disposals
Revaluations
Transfers between classes
Foreign Exchange movement
At 31 March 2022||**Listed**
**Investments**
**£**
17,145,083
15,165,840
(3,697,022)
(1,656,160)
(5,590,306)
449,914
21,817,348| Page 29 **PTEN RESEARCH FOUNDATION** ## **(A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** |**11.**
**Debtors**
**Due within one year**
Prepayments and accrued income
**12.**
**Current asset investments**
Listed investments
**13.**
**Creditors: Amounts falling due within one year**
Trade creditors
Other creditors
Accruals
**14.**
**Financial instruments**
**Financial assets**
Financial assets measured at fair value through income and expenditure||**2022**
**£**
4,592
4,592
**2022**
**£**
6,223,219
**2022**
**£**
6,478
2,627
287,005
296,110
**2022**
**£**
28,040,567|**2021**
**£**
4,445
4,445
**2021**
**£**
7,101,446
**2021**
**£**
16,594
-
586,279
602,873

**2021**

**£**
24,246,529| |---|---|---|---| ||||| ||||| Financial assets measured at fair value through income and expenditure comprise of fixed and current asset investments. Page 30 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **15. Statement of funds** ## **Statement of funds - current year** ||**Balance at**|**Income**|**Expenditure**|**Gains/**||**Balance at**| |---|---|---|---|---|---|---| ||**1 April 2021**|||**(Losses)**|**31 March 2022**|| ||**£**|**£**|**£**|
**£**||**£**| |**Unrestricted funds**||||||| |General Funds|34,212,308|921,274|(3,699,418)|
(1,283,906)||30,150,258| |**Restricted Funds**||||||| |Medical Research|-|3,361|(3,361)|
-||-| |**Total**|34,212,308|924,635|(3,702,779)|
(1,283,906)||30,150,258| |**Medical Research**- To support medical||research taken place into the||PTEN gene and|finding a potential|| |treatment of PHTS.||||||| |**Statement of funds – prior year**||||||| ||**Balance at**|**Income**|**Expenditure**|**Gains/**||**Balance at**| ||**1 April 2020**|||**(Losses)**|**31 March 2021**|| ||**£**|**£**|**£**|
**£**||**£**| |**Unrestricted funds**||||||| |General Funds|37,422,256|722,491|(2,526,367)|
(1,406,072)||34,212,308| |**Restricted Funds**||||||| |Medical Research|3,361|418|(3,779)|
-||-| |**Total**|37,425,617|722,909|(2,530,146)|
(1,406,072)||34,212,308| **Medical Research** - To support medical research taken place into the PTEN gene and finding a potential treatment of PHTS. ## **Statement of funds – prior year** Page 31 **PTEN RESEARCH FOUNDATION** **(A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **16. Analysis of net assets between funds Analysis of net assets between funds - current year** |Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
**Total**
**Analysis of net assets between funds - prior year**
Tangible fixed assets
Fixed asset investments
Current assets
Creditors due within one year
**Total**|**Unrestricted**
**funds**
**2022**
**£**
4,092
21,817,348
8,624,928
(296,110)
30,150,258
**Unrestricted**
**funds**
**2021**
**£**
1,623
17,145,083
17,668,475
(602,873)
34,212,308||**Total**
**funds**
**2022**
**£**
4,092
21,817,348
8,624,928
(296,110)| |---|---|---|---| ||||30,150,258| ||||**Total**
**funds**
**2021**
**£**
1,623
17,145,083
17,668,475
(602,873)
34,212,308| Page 32 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **17. Reconciliation of net movement in funds to net cash flow from operating activities** |**18.**|||**2022**
**£**|**2022**
**£**|**2021**
**£**
(3,213,309)
889
1,792
(722,491)
7,169
489,052
(312,832)
1,509,225
(2,240,505)
**2021**
**£**
10,562,584
10,562,584| |---|---|---|---|---|---| ||||||| ||Net expenditure for the year (as per Statement of Financial
Activities)||(4,062,050)||| ||||||| ||**Adjustments for:**||||| ||Depreciation charges||1,240||| ||Loss on disposal||1,499||| ||Dividends and interests from investments||(921,274)||| ||(Increase)/Decrease in debtors||(147)||| ||(Decrease)/Increase in creditors||(306,763)||| ||Loss/(gain) on investments||1,905,871||| ||Foreign exchange non-cash movements on investments||(621,965)||| ||||||| ||**Total cash and cash equivalents**||(4,003,589)||| ||**Analysis of cash and cash equivalents**
Cash at bank
**Total cash and cash equivalents**||**2022**
**£**
2,397,117
2,397,117||| Page 33 **PTEN RESEARCH FOUNDATION (A company limited by guarantee)** ## **NOTES ON FINANCIAL STATEMENTS** ## **FOR THE YEAR ENDED 31 MARCH 2022** ## **19. Analysis of changes in net debt** ||**At**
**1 April 2021**
**Cash**
**Flows**
**Other non-**
**cash**
**changes**
**At**
**31 March 2022**| |---|---| ||
**£**
**£**
**£**
**£**| |Cash at bank and in hand|10,562,584
(8,180,314)
14,847
2,397,117| |Liquid investments|7,101,446
(1,035,431)
157,204
6,223,219| ||17,664,030
(9,215,745)
172,051
8,620,336| ## **20. Pension commitments** The charity operates a defined contribution pension scheme, pension costs for the year were £58,388 (2020 - £29,511). At the year end, a balance of £2,627 (2021: £Nil) was due to be paid in respect of pensions. ## **21. Operating lease commitments** At 31 March 2022 the Charity had no commitments to make future minimum lease payments under non-cancellable operating leases. |Amounts payable within 1 year|**2022**
**£**
-|**2021**
**£**| |---|---|---| |||-| The following lease payments and changes in lease payments have been recognised in the statement of financial activities: |Operating lease rentals
Changes in lease payments arising from COVID-19 related
rent concessions|**2022**
**£**
-
-
-|**2021**
**£**
48,916
(2,669)| |---|---|---| |||46,247| ## **22. Related party transactions** Apart from the transactions disclosed in note 8, there were no related party transactions in the year. Page 34